In population-based studies of UC and CD, estimates of the increased lifetime risk of CRC have varied from about one to sixfold. [4] [5] [6] Moreover, the largest population-based analysis of clinical characteristics and prognosis in the USA demonstrated a 1.7-fold increased risk of mortality in IBDassociated CRC patients than in the non-IBD associated patients. 6 Therefore, taking early action to prevent the development of CRC is important to prolong survival in these patients. It has been demonstrated that CRC usually develops from chronic intestinal inflammation. 7, 8 Thus, attenuating gut inflammation may be effective in preventing the development of IBD and IBD-associated gastroenterological cancer. Several anti-inflammatory agents, such as thiopurines and mesalazine, are usually prescribed to attenuate intestinal inflammation in patients with IBD. [9] [10] [11] Previous studies reported that the use of 5-aminosalicylic acid (5-ASA) can attenuate intestinal inflammation and decrease the risk of CRC in patients with IBD. 12, 13 However, whether thiopurines can decrease the risk of CRC and dysplasia in IBD patients is controversial.
Thiopurines, consisting of azathioprine (AZA) and mercaptopurine (MP), are anti-metabolite prodrugs that are used as antineoplastics and immunosuppressants in the clinic. 14 They have shown great promise in treating intestinal inflammation due to their low cost, high quality, and stability in inducing disease remission. 15 They are especially useful in patients who do not respond to aminosalicylates or require repeated courses of steroids, according to the third edition of the European Crohn's and Colitis Organization (ECCO) guidelines. 16 However, the antineoplastic effect of thiopurines against CRC or dysplasia in patients with IBD remains controversial. A metaanalysis performed in 2013, consisting of 10 cohort and nine casecontrol studies, demonstrated the protective effect of thiopurines usage against the development of CRC in patients with IBD (odds ratio [OR] = 0.71, 95% CI 0.54-0.94). 17 In contrast, the most recent meta-analysis published in 2014 failed to show similar results (OR = 0.87, 95% CI 0.71-1.06). 18 In the past 3 years, the results of six new clinical studies involving 22 551 participants have been published. [19] [20] [21] [22] [23] [24] To our knowledge, these studies have not been included in any previously published meta-analysis assessing the effect of thiopurines on the risks of developing CRC and dysplasia in patients with IBD.
Therefore, we conducted an updated systematic review and meta-analysis to assess the effect of thiopurines (AZA and MP) on the risks of developing colorectal neoplasia (the early stage of cancer) 25 with the aim of better understanding the antineoplastic effect of thiopurines on decreasing risk of development of IBD-associated colorectal neoplasia in patients with UC or CD. Moreover, subgroup meta-analysis was performed based on different study types, study settings, disease types, outcomes, geographical regions and study publication years.
| MATERIALS AND METHODS

| Search strategies
Two authors (M.L. and X.Q.) performed a systematic search of the PubMed, Web of Science, EMBASE, and Cochrane Central Register of Controlled Trials databases for all articles and abstracts related to the effect of thiopurines on the risk of developing colorectal neoplasia in patients with IBD. The Medical Subject Headings terms and individual corresponding free terms applied in the search included "colitis, ulcerative," "Crohn's Disease," "inflammatory bowel disease,"
"azathioprine," "Mercaptopurine," "thiopurine," "colon* cancer," "colorectal cancer," "dysplasia" and "neoplasia." All searches were updated to August 2017.
| Study selection
The inclusion criteria were as follows: (1) 
| Quality assessment
The Newcastle-Ottawa Scale (NOS) 26 was applied to evaluate the quality of each study. A final score of 0-3 stars was regarded as low quality, 4-6 stars as medium quality, and 7-9 stars as high quality.
| Statistical analysis
The effect of thiopurines on colorectal neoplasia in patients with IBD was expressed as an OR and 95% CI using the DerSimonian and Laird random-effects model. 27 Wherever possible, adjusted ratios were used in the analysis. The ratio that adjusted the most factors was selected. If an adjusted ratio was not available, then the OR was calculated from the raw data provided. As the incidence of colorectal neoplasia in patients with IBD was relatively low, we considered the RR
and HR values to be mathematically approximate to the OR value.
Heterogeneity across studies was tested using the Q and I 2 statistics. For the Q statistic, heterogeneity was considered statistically significant if the P-value was below than .10 using the chi-squared test. in Table 1 . Pooling the 24 studies using a random effect model yielded a protective OR of 0.63 (95% CI 0.46-0.86, Q = 66.71, I 2 = 65.5%; P < .001; Figure 2 ). studies reported the effect of thiopurines on the risk of colorectal neoplasia in patients with UC. In addition, the ORs and 95% CIs for patients with UC and CD patients in one study were calculated from the original data reported, 30 and for another study, data were provided by the corresponding author. 24 A significant beneficial role of thiopurine treatment was found for patients with UC (OR = 0.67, 95% CI 0.45-0.98, Q = 29.14, I 2 = 55.4%, P = .006). However, no beneficial role of thiopurines was found in CD patients (OR = 1.06, 95% CI 0.54-2.09, Q = 0.38, I 2 = 0.0%, P = .535; Figure 3 ).
| Effect of thiopurines on the risk of colorectal neoplasia based on IBD type (UC and CD)
| Effect of thiopurines on the risk of CRC, advanced colorectal neoplasia (CRC/HGD), and dysplasia in IBD patients
In this meta-analysis, we further divided the studies into three Figure 7 ).
| Meta-regression analysis of the different publication years
A meta-regression analysis of the antineoplastic effect of thiopurines in studies with different publication years was performed.
A slight tendency towards an increased protective effect of thiopurines in more recent studies. However, this result was not significant (P = .240; Figure S1 ). 
| Publication bias
No publication bias was detected among the 24 studies according to the Begg's funnel plot and Egger's publication bias plot (P = .240
and P = .200, respectively; Figure S2 ). Tung (2001) Fraser (2002) Rutter (2004) Matula (2005) Lakatos (2006) Velayos (2006) Gupta (2007) Tang (2010) Baars (2011) Setshedi (2011) Schaik (2011) Garcia (2013) Pasternak (2013) Satchi (2013) Rubin (2013) Nieminen (2013) Kopylov (2015) Gordillo (2015) Desai (2015) Nowacki (2015) Cheddani (2016) Carrat (2017) Overall (I-squared = 65.5%, P = .000) NOTE: Weights are from random effects analysis We found a protective effect of thiopurines in UC (OR = 0.67, 95% CI 0.45-0.98) but not in CD (OR = 1.06, 95% CI 0.54-2.09). It is worth noting that about 30% CD patients have no colonic disease. 51 As the original studies included did not specify whether they have excluded the CD patients with only small-intestine involvement clearly when assessing the effect of thiopurines on colorectal neoplasia in CD patients, the overall protective effect of thiopurines in CD could be underestimated. Tung (2001) Fraser (2002) Rutter (2004) Matula (2005) Lakatos (2006) Velayos (2006) Gupta (2007) Rubin (2013) Gordillo (2015) Desai (2015) Nowacki (2015) Carrat ( (2013) Rubin (2013) Nieminen (2013) Kopylov (2015) Desai (2015) Nowacki (2015) Cheddani (2016) Carrat (2017) CRC/HGD Connell (1994) Fraser (2002) Rutter (2004) Matula (2005) Lakatos (2006) Velayos (2006) Gupta (2007) Tang (2010) Baars ( (2015) Desai (2015) Gordillo (2015) Nowacki (2015) Cheddani (2016) However, as the patients with UC could already have colonic dysplasia that has gone undetected before the thiopurine treatment, the protective effect of thiopurines in decreasing the risk of dysplasia could be underestimate.
In this meta-analysis, thiopurine use was associated with a signif- Tung (2001) Fraser (2002) Rutter (2004) Matula (2005) Velayos (2006) Gupta (2007) Tang (2010) Baars (2011) Setshedi (2011) Garcia (2013) Satchi (2013) Rubin (2013) Nieminen (2013) Gordillo (2015) Desai (2015) Nowacki (2015) Carrat ( However, only five studies 34, 35, 37, 39, 44 reported thiopurine dose, which had no significant effect in reducing the risk of colorectal neoplasia (OR = 0.69, 95% CI 0.23-2.07).
We also performed a sub-meta-analysis to study the antineoplas- Fraser (2002) Matula (2005) Lakatos (2006) Gupta (2007) Setshedi (2011) Schaik (2011) Garcia (2013) Pasternak (2013) Satchi (2013) Kopylov (2015) Desai (2015) Nowacki (2015) Cheddani (2016) Tung (2001) Rutter (2004) Velayos (2006) Tang (2010) Baars (2011) Rubin ( Several limitations should be considered in this meta-analysis.
First, the I 2 statistic from the heterogeneity test was 65.5%, revealing moderate heterogeneity among the 24 studies included. To decrease the heterogeneity between studies, we performed subgroup analysis by different IBD types, study designs, settings and publication years respectively. However, even if we stratified the total 24 studies into different sub-groups by a certain confounding factor (eg, IBD types), the other confounders (eg, study designs, settings and publication years, etc.) still remained and could influence the heterogeneity considerably. Similar predicaments were also reported in the two previously published meta-analyses. 17, 18 Moreover, other confounding factors, such as disease duration, severity of inflammation, drug duration and dosage, and concomitant medication, were not well controlled in some of the included studies.
Patients who received thiopurines were more often exposed to corticosteroids than those who did not receive thiopurines. Second, the proportions of thiopurines users among IBD patients differed Gordillo (2015) Nowacki (2015) Cheddani (2016) Carrat (2017) Lashner ( 
| CONCLUSION
In conclusion, our pooled analysis suggests a significant protective effect thiopurine treatment on the risk of colorectal neoplasia in IBD patients, particularly amongst patients with UC. However, no such evidence was found in patients with CD. Although the effect of thiopurines could be influenced by different settings, study designs, and countries, this meta-analysis have provided some preliminary data on thiopurines in preventing colonic neoplasia in IBD patients.
Further prospective research is warranted to explore the exact association for several critical issues, such as the severity and extent of disease, or the dosage and duration of drug treatment. Tung (2001) Fraser (2002) Rutter (2004) Matula (2005) 2006-2017
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Subtotal (I-squared = 64.9% P = .014) F I G U R E 8 Forest plot of sub-analyses of thiopurines on the risk of colorectal neoplasia in patients with IBD from studies conducted in different publication years. Size of boxes is proportional to weight of the individual study. The relative weighted contribution of each of the studies to the overall pooled adjusted odds ratio (OR) is shown on the far right. CI, confidence interval. IBD, inflammatory bowel disease
